首頁 > 市場調查報告書 > 製藥

神經疾病

癲癇藥物市場規模和預測、全球和地區佔有率、趨勢以及按治療、配銷通路和地理分類的成長機會分析

市場調查報告書

商品編碼

1389654

癲癇藥物市場規模和預測、全球和地區佔有率、趨勢以及按治療、配銷通路和地理分類的成長機會分析

Epilepsy Drugs Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography

出版日期: 2023年11月06日 | 出版商:

The Insight Partners | 英文 139 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年癲癇藥物市場規模為77.68億美元，預計2030年將達到107.05億美元；預計2022年至2030年的CAGR為4.1%。癲癇藥物市場的成長主要是由癲癇盛行率的增加和老年人數量的增加所推動的。

癲癇是一種神經系統疾病，可引起癲癇發作並影響全球數百萬人。癲癇藥物也稱為抗癲癇藥物（AED），通常用於治療癲癇，因為它有助於更好地管理癲癇患者的癲癇發作。一些抗藥性癲癇患者選擇其他治療方法，例如手術和植入大腦的裝置以幫助控制癲癇發作。

幾種癲癇藥物專利即將到期，為癲癇藥物市場成長創造機會

預計未來幾年癲癇藥物市場的許多專利將到期。它可能會增加學名藥的滲透率，以減少醫療費用。這將為其他市場參與者創造更多機會。以下提到的是一些在未來幾年內專利即將到期的藥物。

公司專利專利有效期限成分處理

住友製藥公司 US9206135 2026年4月21日醋酸艾斯利卡西平部分發作性癲癇發作

葛蘭素史克 US7919115 2029 年 1 月 4 日拉莫三嗪癲癇

Ucb Inc USRE38551 2022 年 3 月 17 日拉科醯胺癲癇與局部發作癲癇

SK Biopharmaceuticals US7598279 2027 年 10 月 30 日 CENOBAMATE 局部性癲癇

SUPERNUS PHARMS US8877248 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US9555004 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US10314790 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8663683 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US9622983 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8298580 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8992989 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8889191 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US9549940 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8298576 2028 年 4 月托吡酯癲癇緩釋製劑

基於治療的見解

癲癇藥物市場依治療方法分為第一代抗癲癇藥、第二代抗癲癇藥和第三代抗癲癇藥。 2022年，第二代抗癲癇藥物佔最大市場；第三代抗癲癇藥物預計在 2022 年至 2030 年期間複合CAGR最快。第二代AED包括非氨酯、加巴噴丁、拉莫三嗪、左乙拉西坦、奧卡西平、普加巴林、盧非醯胺、司替噴醇、噻加賓、托吡酯、托吡酯、氨己烯酸和唑尼沙胺。在北美和歐洲，ZNS也被認為是第二代藥物。與第一代藥物相比，第二代 AED 的成本較高，這是限制其在處方集中提及的重要因素。與第一代藥物相比，第二代 AED 具有更有利的副作用和更低的致畸風險。許多第一代和一些第二代 (AED) 具有酶誘導的共同特徵，可以增加細胞色素 p450 酶靶向的不同底物的代謝，同時減少誘導劑的作用。

基於配銷通路的見解

癲癇藥物市場依配銷通路分為醫院藥房、零售藥局等。 2022年，醫院藥局細分市場佔最大市場佔有率；零售藥局領域預計在 2022 年至 2030 年期間CAGR最快。醫院藥局從不同公司採購藥品，供應給醫院門診或住院治療。醫院藥房通常提供適用於心臟病學、神經學、泌尿學、病理學、血液學和皮膚科的治療和重症監護藥物。醫院藥局是任何國家醫療保健系統的重要組成部分之一。這些藥房備有癲癇藥物庫存，以確保患者隨時可用。因此，醫院藥局佔有相當大的癲癇藥物市場規模。

在準備癲癇藥物市場報告時提到的一些主要一手和二手來源包括世界衛生組織（WHO）、疾病管制與預防中心（CDC）、國家生物技術資訊中心（NCBI）、投資者介紹以及市場參與者的年度報告。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 法國
- 英國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 10 章：癲癇藥物市場-產業格局

概述
癲癇藥物市場的成長策略
無機成長策略
- 概述
有機成長策略
- 概述

第 11 章：公司簡介

UCB SA
Novartis AG
Pfizer Inc
GSK Plc
Abbott Laboratories
Sanofi SA
Sumitomo Pharma America Inc.
Teva Pharmaceutical Industries Ltd
Catalyst Pharmaceuticals Inc
Alkem Laboratories Ltd

第 12 章：附錄

關於我們
專業術語

簡介目錄圖表

Product Code: TIPRE00024323

The epilepsy drugs market size was valued at US$ 7.768 billion in 2022 and is projected to reach US$ 10.705 billion by 2030; it is estimated to register a CAGR of 4.1% from 2022 to 2030. The epilepsy drugs market growth is primarily driven by the increasing prevalence of epilepsy and an increasing number of elderly people.

Epilepsy is a neurological condition that can cause seizures and affects millions of people globally. Epilepsy drugs are also known as anti-epileptic drugs (AEDs), which are commonly used for the treatment of epilepsy as it helps in the better management of seizures among epilepsy patients. Some of the patients with drugs resistance epilepsy opt for other treatment methods such as surgery and devices that are implanted in the brain to helps in seizure management.

Several Epilepsy Drugs Nearing Patent Expiration Creating Opportunities for Epilepsy Drugs Market Growth

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Treatment-Based Insights

The epilepsy drugs market, by treatment, is segmented into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. In 2022, the second generation anti-epileptics segment held the largest market share; the third generation anti-epileptics is estimated to register the fastest CAGR during 2022-2030. The second-generation AEDs include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and zonisamide. In North America and Europe, ZNS is also considered a second-generation drug. The higher cost of second-generation AEDs compared with first-generation drugs is a significant factor limiting their mention in formularies. The second-generation AEDs have a more favorable side-effect profile and a lower risk of teratogenesis compared with first-generation drugs. Many first-generation and several second-generation (AEDs) share a common feature of enzyme induction that can increase the metabolism of different substrates targeted by the cytochrome p450 enzyme, along with a decrease in the action of the inducer.

Distribution Channel-Based Insights

The epilepsy drugs market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy stores, and others. In 2022, the hospital pharmacies segment held the largest market share; the retail pharmacy segment is anticipated to register the fastest CAGR during 2022-2030. Hospital pharmacies purchase pharmaceuticals from different companies and supply them to hospitals for outpatient or inpatient treatments. Hospital pharmacies usually offer therapeutic and critical care drugs that have applications in cardiology, neurology, urology, pathology, hematology, and dermatology. Hospital pharmacies are among the essential parts of the healthcare system of any country. These pharmacies maintain stocks of epilepsy drugs to ensure their ready availability for patients. Thus, hospital pharmacies hold a considerable size of the epilepsy drug market.

A few of the major primary and secondary sources referred to while preparing the report on the epilepsy drugs market are the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Investor presentations and Annual Reports of Market players.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the epilepsy drugs market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global epilepsy drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the epilepsy drugs market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Epilepsy Drugs Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis

5. Epilepsy Drugs Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
- 5.4.1 Increasing Product Approvals
5.5 Impact Analysis

6. Epilepsy Drugs Market - Global Market Analysis

6.1 Epilepsy Drugs Revenue (US$ Mn), 2022 - 2030

7. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Global Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Epilepsy Drugs Market - Revenue and Forecast to 2030 - Geographic Analysis

9.1 North America: Epilepsy Drugs Market
- 9.1.1 Overview
- 9.1.2 North America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.1.3 North America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.1.4 North America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.4.1 US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.1.1 Overview
    - 9.1.4.1.2 US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.1.3 US: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.4.1.4 US: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.4.2 Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.2.1 Overview
    - 9.1.4.2.2 Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.2.3 Canada: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.4.2.4 Canada: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.4.3 Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.3.1 Overview
    - 9.1.4.3.2 Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.4.3.3 Mexico: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.4.3.4 Mexico: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.2 Europe: Epilepsy Drugs Market
- 9.2.1 Overview
- 9.2.2 Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.2.3 Europe: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.2.4 Europe: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.2.5 Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
  - 9.2.5.1 Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.1.1 Overview
    - 9.2.5.1.2 Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.1.3 Germany: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.1.4 Germany: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.2 France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.2.1 Overview
    - 9.2.5.2.2 France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.2.3 France: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.2.4 France: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.3 UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.3.1 Overview
    - 9.2.5.3.2 UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.3.3 UK: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.3.4 UK: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.4 Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.4.1 Overview
    - 9.2.5.4.2 Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.4.3 Italy: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.4.4 Italy: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.5 Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.5.1 Overview
    - 9.2.5.5.2 Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.5.3 Spain: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.5.4 Spain: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.2.5.6 Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.6.1 Overview
    - 9.2.5.6.2 Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.2.5.6.3 Rest of Europe: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.2.5.6.4 Rest of Europe: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.3 Asia Pacific: Epilepsy Drugs Market
- 9.3.1 Overview
- 9.3.2 Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.3.3 Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.3.4 Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.3.5 Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
  - 9.3.5.1 China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.1.1 Overview
    - 9.3.5.1.2 China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.1.3 China: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.1.4 China: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.2 Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.2.1 Overview
    - 9.3.5.2.2 Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.2.3 Japan: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.2.4 Japan: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.3 India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.3.1 Overview
    - 9.3.5.3.2 India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.3.3 India: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.3.4 India: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.4 Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.4.1 Overview
    - 9.3.5.4.2 Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.4.3 Australia: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.4.4 Australia: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.5 South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.5.1 Overview
    - 9.3.5.5.2 South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.5.3 South Korea: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.5.4 South Korea: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.3.5.6 Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.6.1 Overview
    - 9.3.5.6.2 Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.3.5.6.3 Rest of Asia Pacific: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.3.5.6.4 Rest of Asia Pacific: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.4 Middle East & Africa Epilepsy Drugs Market
- 9.4.1 Overview
- 9.4.2 Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4.3 Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.4.4 Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.1 South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.1.1 Overview
    - 9.4.4.1.2 South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.1.3 South Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.1.4 South Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.2 Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.2.1 Overview
    - 9.4.4.2.2 Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.2.3 Saudi Arabia: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.2.4 Saudi Arabia: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.3 UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.3.1 Overview
    - 9.4.4.3.2 UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.3.3 UAE: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.3.4 UAE: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.4.1 Overview
    - 9.4.4.4.2 Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.4.4.4.3 Rest of Middle East & Africa: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.4.4.4.4 Rest of Middle East & Africa: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.5 South & Central America: Epilepsy Drugs Market
- 9.5.1 Overview
- 9.5.2 South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5.3 South & Central America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
- 9.5.4 South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
- 9.5.5 South & Central America: Epilepsy Drugs Market Share by Country - 2022 & 2030, (%)
  - 9.5.5.1 Brazil: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.1.1 Overview
    - 9.5.5.1.2 Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
    - 9.5.5.1.3 Brazil: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.5.5.1.4 Brazil: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.5.5.2 Argentina: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.2.1 Overview
    - 9.5.5.2.2 Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
    - 9.5.5.2.3 Argentina: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.5.5.2.4 Argentina: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.5.5.3 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.3.1 Overview
    - 9.5.5.3.2 Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.5.5.3.3 Rest of South & Central America: Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.5.5.3.4 Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 UCB SA
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novartis AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Pfizer Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 GSK Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Abbott Laboratories
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sanofi SA
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Sumitomo Pharma America Inc.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Catalyst Pharmaceuticals Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Alkem Laboratories Ltd
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Epilepsy Drugs Segmentation
Table 2. North America Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 4. US Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 5. US Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 6. Canada Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 7. Canada Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 8. Mexico Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 9. Mexico Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. France Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 15. France Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 16. UK Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 17. UK Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Europe Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 25. Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 26. China Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 27. China Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 28. Japan Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 29. Japan Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 30. India Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 31. India Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 32. Australia Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 33. Australia Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. South Korea Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 35. South Korea Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 37. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 38. Middle East & Africa Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 39. Middle East & Africa Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 40. South Africa Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 41. South Africa Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 42. Saudi Arabia Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 43. Saudi Arabia Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 44. UAE Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 45. UAE Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 46. Rest of Middle East & Africa Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Middle East & Africa Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 48. South & Central America: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 49. South & Central America: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 50. Brazil: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 51. Brazil: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 52. Argentina: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 53. Argentina: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 54. Rest of South & Central America: Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 55. Rest of South & Central America: Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 56. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 57. Recent Organic Growth Strategies in the Epilepsy Drugs Market
Table 58. Glossary of Terms, Epilepsy Drugs Market

List Of Figures

Figure 1. Epilepsy Drugs Segmentation, By Geography
Figure 2. Global - PEST Analysis
Figure 3. Epilepsy Drugs Market: Key Industry Dynamics
Figure 4. Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 5. Epilepsy Drugs Revenue (US$ Mn), 2022 - 2030
Figure 6. Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 7. First Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Second Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Third Generation Anti-epileptics: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 11. Hospital Pharmacy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Retail Pharmacy Stores: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 15. North America Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. North America: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 17. US: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Canada: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Mexico: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Europe: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 21. Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 23. Germany: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. France: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. UK: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. Italy: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Spain: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Rest of Europe: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. Asia Pacific: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 30. Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Asia Pacific: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 32. China: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 33. Japan: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 34. India: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 35. Australia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 36. South Korea: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 37. Rest of Asia Pacific: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 38. Middle East & Africa: Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 39. Middle East & Africa Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 40. Middle East & Africa: Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 41. South Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 42. Saudi Arabia: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 43. UAE: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 44. Rest of Middle East & Africa: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 45. South & Central America: Epilepsy Drugs Market, By Key Country - Revenue (2022) (US$ Million)
Figure 46. South & Central America: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 47. South & Central America: Epilepsy Drugs Market Share by Country - 2022 & 2030, (%)
Figure 48. Brazil: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 49. Argentina: Epilepsy Drugs Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 50. Rest of South & Central America: Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. Growth Strategies in the Epilepsy Drugs Market